Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 100

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 100
---
, the handling of biological samples, or the cross -bordertransfer of biological data, we may need to adjust our operations to adapt to these regulations. Any new regulations could be more stringent than those in place in the countries where our tests are developed and used, potentially affecting the scope or method of service delivery. Further, new regulations may mandate additional oversight regarding the professionals authorized to conduct tests, analyze results, or sign reports. Such requirements could conflict with our existing agreements with distribution partners, laboratories, and healthcare professionals. In that case, we may be forced to renegotiate existing agreements, potentially incurring additional costs and delays. If we are unable to adapt to these regulatory changes effectively, or if we face challenges in securing the necessary authorizations under new frameworks, it could materially impact our business operations, financial condition and growth prospects. We are subject to risks associated with transactions denominated in foreign currency and with currency exchange rate fluctuations, which could adversely affect our operating results. As a result of our international operations, we receive a portion of our revenues and pay a portion of our expenses in currencies other than the U.S. dollar, such as the Mexican and Argentinian pesos, in particular as substantially all of our sales are made in Argentina. In addition, many of our distribution agreements contain clauses requiring regular 26 U.S. dollar price re -adjustmentsto account for fluctuations in the exchange rate between the U.S. dollar and the local currency. As a result, we are at risk from exchange rate fluctuations between such foreign currencies and the U.S. dollar, which could adversely affect our results of operations. See “ — Adverse economic or market conditions, including inflation and the global macroeconomic environment, could negatively impact our business, financial condition and results of operations.” Additionally, the volume of our international orders may be negatively impacted by the U.S. dollar. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. If the U.S. dollar strengthens against foreign currencies, the translation of these foreign currency denominated transactions will result in decreased revenues and operating expenses. We may not be able to offset adverse foreign currency impact with increased revenues. Even with this strategy in place to mitigate balance sheet foreign currency risk, we will not eliminate our exposure to foreign exchange rate fluctuations on our financial results. We are subject to risks related to taxation in multiple jurisdictions. We are subject to income taxes in both the United States and numerous foreign jurisdictions. Significant judgments based on interpretations of existing tax laws or